Oculis Trial Shows Potential for Optical Neuroprotective Therapy
By Karen Roman Oculis Holding AG (Nasdaq: OCS) said Phase 2 of its neuroprotective candidate OCS-05 met key endpoints of ...
PsyPost on MSN4d
Mediterranean diet’s neuroprotective effects linked to glycemic control
Recent research has uncovered a link between diet, blood sugar control, and brain health in aging adults. The study, ...
Multiple Sclerosis News Today2h
OCS-05 shows safety, aids vision with optic neuritis in Phase 2 trial
OCS-05 was well tolerated and improved vision and eye health in a Phase 2 trial in 33 people with optic neuritis due to MS or ...
devdiscourse6d
Breakthrough in Parkinson’s Research: Nano-Melatonin Shows Enhanced Neuroprotective Properties
Recent studies have identified the significance of mitophagy, a quality control process that removes dysfunctional ...
AI aids in discovery of potential glaucoma drug candidates
Glaucoma is a progressive eye disorder characterized by fluid buildup inside the eye, causing ocular hypertension. By 2040, ...
Oculis Holding’s OCS-05 Shows Promising Results in Phase 2 Trial for Acute Optic Neuritis
Oculis Holding ( (OCS) ) has issued an update. Oculis Holding has announced positive results from a Phase 2 trial for OCS-05, a potential first-in-class neuroprotective therapy for acute optic ...
Drexel University5y
Preclinical Optimization of a Novel Neuroprotective Agent to Treat Parkinson’s Disease
Huntington’s Disease (HD) is a fatally inherited neurodegenerative, orphan disorder affecting 1 in 10,000 individuals with a higher prevalence in Caucasian race. HD is caused by an expanded glutamine ...
Nature5y
Indip—a novel neuroprotective agent?
Crucially, neuronal damage was also significantly reduced in rats treated with Indip 120 min after transient middle cerebral artery occlusion, which suggests that this agent has neuroprotective ...
Pharmabiz1d
Oculis Holding’s OCS-05 phase 2 ACUITY trial in acute optic neuritis meets primary safety endpoint and key secondary efficacy endpoints
Oculis Holding’s OCS-05 phase 2 ACUITY trial in acute optic neuritis meets primary safety endpoint and key secondary efficacy endpoints: Zug, Switzerland Tuesday, January 7, 202 ...